Rendell Marc S
a The Rose Salter Medical Research Foundation , Omaha , NE , USA.
b The Association of Diabetes Investigators , Omaha , NE , USA.
Expert Opin Biol Ther. 2016 Dec;16(12):1557-1569. doi: 10.1080/14712598.2016.1240780. Epub 2016 Oct 3.
Albiglutide is a long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection. Area covered: The pharmacokinetic and pharmacodynamic properties of albiglutide and its clinical effects are discussed. The review encompassed a search of PubMed and a thorough analysis of the European Union and US Food and Drug Administration approval documents. Expert opinion: Albiglutide has a chemical structure quite distinct from that of other marketed GLP-1 RAs. The agent has less gastrointestinal side effects than other comparable GLP-1 RAs and is safe in patients with renal failure. As a sole treatment for diabetes and used with other hypoglycemic agents, it achieves a lowering of HbA1c of up to 1%, less than several competitor GLP-1 RAs. The benefit on weight reduction is minimal compared to other GLP-1 RAs. There exists concern about an imbalance of pancreatitis cases in the approval program as well as injection site reactions which led to discontinuance of therapy in up to 2% of participants. A large long term study now underway will determine if albiglutide, with its lower level of GI intolerance, has a place in the treatment of patients with increased risk of cardiovascular events.
阿必鲁肽是一种长效胰高血糖素样肽-1受体激动剂（GLP-1 RA），通过每周注射给药。涵盖领域：讨论了阿必鲁肽的药代动力学和药效学特性及其临床效果。该综述包括对PubMed的检索以及对欧盟和美国食品药品监督管理局批准文件的全面分析。专家观点：阿必鲁肽的化学结构与其他已上市的GLP-1 RA有很大不同。与其他同类GLP-1 RA相比，该药物的胃肠道副作用较少，对肾衰竭患者安全。作为糖尿病的单一治疗药物以及与其他降糖药物联合使用时，它可使糖化血红蛋白（HbA1c）降低高达1%，低于几种竞争的GLP-1 RA。与其他GLP-1 RA相比，其在减轻体重方面的益处最小。在批准程序中存在对胰腺炎病例失衡以及注射部位反应的担忧，这些反应导致高达2%的参与者停止治疗。目前正在进行的一项大型长期研究将确定胃肠道不耐受程度较低的阿必鲁肽在治疗心血管事件风险增加的患者中是否有一席之地。
